The FDA has approved Onswik (insulin efsitora alfa-gobe), a long-acting insulin injected once a week, for adults with type 2 diabetes, along with diet and exercise. The agency's 2026 novel drug approvals list dates the approval to Sept. 23, and Eli Lilly announced it the next day. The label says Onswik is not recommended for people with type 1 diabetes because of an increased risk of severe low blood sugar, and its safety and effectiveness have not been established in children.
For adults who take daily basal insulin, the draw is convenience, not a stronger effect. Lilly's clinical trials showed Onswik lowered blood sugar about as well as daily insulin, not better. Onswik is the second weekly basal insulin approved in the United States, following Novo Nordisk's Awiqli in March.
As Effective as Daily Insulin, Not Proven Better
The approval rests on four Phase 3 QWINT trials involving more than 3,400 adults with type 2 diabetes, according to Lilly's announcement. In each trial, Onswik met its main goal of noninferior A1C reduction compared with daily insulin glargine or insulin degludec. Noninferior means it was not meaningfully worse, within a preset margin of 0.4 percentage points.
The results were close. In QWINT-1, A1C fell 1.19 points with Onswik and 1.16 points with glargine after 52 weeks, and in QWINT-4, the drops were 1.01 and 1.00 points, HCPLive reported. Moderate-to-severe low blood sugar was less frequent with Onswik in QWINT-1 but not significantly different in the other three trials. In QWINT-3, serious adverse events occurred in 16% of Onswik users and 11% of degludec users, and the most common were cardiovascular-related in both groups.
In QWINT-1, people starting insulin for the first time needed a median of two dose adjustments on Onswik compared with eight on glargine, which may matter to patients who find frequent adjustments hard to manage. Those patients started at 100 units a week, with fixed increases to 150, 250, and 400 units at four-week intervals as needed. In QWINT-2, time spent in the target glucose range was 64.3% with Onswik and 61.2% with degludec.
These were randomized, open-label trials, meaning patients and doctors knew which insulin was used. They were sponsored by Lilly; QWINT-1 and QWINT-2 were published in The New England Journal of Medicine, and QWINT-3 and QWINT-4 in The Lancet. The trials showed comparable blood sugar control but did not show that Onswik is safer or more effective than daily insulin.
Type 1 Limits, Side Effects, and Dosing Cautions
The type 1 limitation is the most important restriction. People with type 1 diabetes make little or no insulin of their own, so dosing errors and low blood sugar can escalate quickly, and the label cites an increased risk of severe hypoglycemia in this group.
Common side effects include low blood sugar, allergic reactions, injection-site reactions, skin thickening or pits where the shot is given, itching, rash, swelling of the hands and feet, and weight gain. The prescribing information also warns of serious risks, including severe allergic reactions, low potassium, and heart failure when taken with diabetes pills called thiazolidinediones, or TZDs. Signs of low blood sugar include shakiness, sweating, dizziness, confusion, blurred vision, fast heartbeat, and hunger.
Dosing works differently from daily insulin, and mistakes are a real concern. The KwikPen comes in two concentrated strengths that deliver up to 400 or 800 units in one injection. Lilly warns patients never to draw the insulin out of the pen with a syringe and to check the pen label before every dose to avoid mix-ups. People who are blind or have vision problems should not use the pen without help from someone trained to use it.
Onswik should not be used in an insulin pump or injected into a vein or muscle. The prescribing information says it is not recommended during pregnancy or breastfeeding, so people who are pregnant, planning a pregnancy, or breastfeeding should talk with their clinician. Lilly also advises against driving or operating heavy machinery until a patient knows how the insulin affects them.
Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, said, "delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes." The weekly schedule means about 52 injections a year instead of roughly 365. A missed dose should be taken as soon as possible within four days, followed by the regular weekly schedule, and patients should never change or switch insulin without guidance from a clinician.
Cost, Availability, and Questions to Ask a Clinician
Lilly says the Onswik KwikPen will reach U.S. pharmacies in the coming months. The company has not announced a price, and insurers have not said whether or how they will cover it. MedicalDaily previously reported that the first weekly insulin reached 70,000 U.S. pharmacies after its launch, and competition may eventually affect pricing.
Patients who find daily injections hard to keep up with can ask whether a weekly insulin makes sense for them. Useful questions include how to recognize and treat low blood sugar, what to do after a missed dose, and whether kidney or liver problems, heart failure, pregnancy plans, or TZD use change the decision. Severe symptoms such as confusion, fainting, or seizures from low blood sugar require emergency care.
Onswik has also received regulatory approval in the European Union, Mexico, and Japan. Real-world safety data, pricing, and insurance decisions will shape how widely it is used.
Key Questions Answered
What did the FDA approve?
Onswik, a once-weekly basal insulin for adults with type 2 diabetes, used along with diet and exercise.
Can people with type 1 diabetes use it?
The label says Onswik is not recommended for people with type 1 diabetes because of an increased risk of severe low blood sugar.
Is it better than daily insulin?
The trials showed it lowered A1C about as well as daily insulin, not better. Rates of moderate-to-severe low blood sugar were similar in three of the four trials and lower with Onswik in one.
What are the main side effects?
Low blood sugar, allergic and injection-site reactions, skin changes at the injection site, itching, rash, swelling of the hands and feet, and weight gain.
When will it be available and how much will it cost?
Lilly says it will be available in the coming months. A price has not been announced, and insurance coverage is not yet known.
Published by Medicaldaily.com
